Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 91Carcinoma, Non-Small-Cell Lung 53Lung Neoplasms 22Hodgkin Disease 15Recurrence 11Lymphoma 10Neoplasm Metastasis 9Prostatic Neoplasms 7Triple Negative Breast Neoplasms 6Neoplasms 6Sarcoma 4Rhabdomyosarcoma 4Lymphoma, Non-Hodgkin 4Lymphoma, Large B-Cell, Diffuse 4Adenocarcinoma of Lung 4Multiple Myeloma 3Mesothelioma, Malignant 3Mesothelioma 3Breast Neoplasms, Male 3Uterine Cervical Neoplasms 2Ovarian Neoplasms 2Neuroblastoma 2Melanoma 2Lymphoma, Large-Cell, Anaplastic 2HER2-negative Breast Cancer 2Fallopian Tube Neoplasms 2Esophageal Squamous Cell Carcinoma 2Colonic Neoplasms 2Brain Neoplasms 2Advanced Breast Cancer 2

Interventions

zenocutuzumab 2exemestane 1Vinorelbine 1Trastuzumab 1Letrozole 1Fulvestrant 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Lethal Congenital Contracture Syndrome 2 × Vinorelbine × Clear all
NCT03321981 2024-03-07

MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.

Merus B.V.

Phase 2 Completed
105 enrolled 23 charts

Lethal Congenital Contracture Syndrome 2

Data powered by HemOnc (CC BY 4.0) Colophon âš¡